Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- VarmX B.V.
- Study ID
- NCT07288489
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Blood Loss, Surgical
- Coagulation Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- VMX-C001 — DRUGA fixed dose of VMX-C001 will be administered prior to commencement of procedure.
- Usual Pharmacological Care — DRUGUsual pharmacological care should be treatment planned to restore coagulation or support haemostasis for the required procedure.
Study Details
The goal of this clinical trial is to learn if VMX-C001 works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that carry a high risk of bleeding. The main question it aims to answer is: ● What is the proportion of participants in whom the stopping of bleeding was classed as good or excellent during the procedure, as judged by a group of experts who did not know which treatment was given? Researchers will compare a fixed dose of VMX-C001 to the usual treatment that would be given for the required procedure. Participants will: * Be given either a fixed dose of VMX-C001 or usual treatment before they undergo the required procedure in theatre * Have regular clinical assessments, including laboratory tests, during their hospital stay following the procedure * Return to the clinic for a check-up and tests approximately 28 days after the procedure was conducted.
Key Dates
- Start date
- Mar 31, 2026
- Status verified
- Feb 2026
- Primary completion
- Jan 31, 2029
- Completion
- Jan 31, 2031
Study Design
- Enrollment
- 800 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: VMX-C001Participants will be administered a fixed dose of VMX-C001 before undergoing the required procedure.
- Active Comparator: Usual Pharmacological CareParticipants will be given the usual treatment used by the site for patients receiving FXa DOACs when undergoing the required procedure.
Primary Outcome Measure
Effect of VMX-C001 versus usual pharmacological care on haemostasis [ Time Frame: From start to end of required procedure (Day 1). ]
Central Contacts
- Head of Clinical Operations+43 664 88375193
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Chandler Regional Medical Center (CRMC) | Chandler | Arizona | 85224 | - |
| HonorHealth John C Lincoln Medical Center | Phoenix | Arizona | 85020 | - |
| St. Joseph's Hospital and Medical Center | Phoenix | Arizona | 85013 | - |
| Stanford Hospital and Clinics | Stanford | California | 94305 | - |
| Denver Metro Orthopedics, P.C. - Englewood Location | Englewood | Colorado | 80113 | - |
| Medical Center of the Rockies | Fort Collins | Colorado | 80523 | - |
| Christiana Care | Newark | Delaware | 19718 | - |
| University of South Florida | Tampa | Florida | 33606 | - |
| University of Iowa Health Care | Iowa City | Iowa | 52242 | - |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | - |
| Beaumont Hospital, Royal Oak | Royal Oak | Michigan | 48073 | - |
| William Beaumont Hospital - Troy Campus | Troy | Michigan | 48085 | - |
| Duke University Medical Center | Durham | North Carolina | 27710 | - |
| The University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73126 | - |
| Texas Tech University Health Sciences Center - El Paso | El Paso | Texas | 79905 | - |
| The University of Texas McGovern Medical School at Houston | Houston | Texas | 77030 | - |
Find similar trials in Chandler, AZ
Related Studies
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent SurgeryPHASE3 · Recruiting · Takeda · Arkansas City, Arkansas
- Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine AtonyPHASE2 · Recruiting · University of Michigan · Ann Arbor, Michigan
- Quantra QPlus in Pediatric Cardiovascular ProceduresNot Yet Recruiting · HemoSonics LLC · Los Angeles, California